Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

CuraLin Herbal Supplement for Type 2 Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT05267925
Recruitment Status : Suspended (Pending additional product QA)
First Posted : March 7, 2022
Last Update Posted : April 22, 2022
Information provided by (Responsible Party):
National University of Natural Medicine

Brief Summary:
The purpose of this study is to provide preliminary data necessary for a larger, controlled trial of CuraLin as a treatment option for T2DM. This study will also fill the gap in literature surrounding herbal medicine in the treatment of T2DM. The use of herbal preparations for diabetes has increased globally, and given the costs, adverse effects, lack of clinical outcome improvement, and minimal A1c reductions associated with medications, safer, more affordable alternatives need to be explored. CuraLin™ is a dietary supplement manufactured by NutraStar Inc. and sold by CuraLife; it is a blend of nine ayurvedic plants and herbs taken three times daily, after meals for the management of diabetes. It is hypothesized that CuraLin will be safely tolerated among adults with Type 2 Diabetes Mellitus, and will improve glucose control and cardiometabolic risk factors over this 12 week study.

Condition or disease Intervention/treatment Phase
Type 2 Diabetes Dietary Supplement: CuraLin Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Single-arm, Open Label Clinical Trial of CuraLin in Type 2 Diabetes
Actual Study Start Date : January 8, 2022
Estimated Primary Completion Date : December 31, 2022
Estimated Study Completion Date : December 31, 2022

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Intervention
All participants will be asked to take the dietary herbal supplement CuraLin for the duration of the study. All participants will take 2 capsules orally, three times per day following meals for 12 weeks.
Dietary Supplement: CuraLin

CuraLin™ is a dietary supplement manufactured by NutraStar Inc. and sold by CuraLife; it is a blend of nine ayurvedic plants and herbs.

The CuraLin formulation contains the following ingredients (per 2 capsules):

  • Mormordica charantia (fruit) - 300mg
  • Gymnema sylvestre (leaf) - 80mg
  • Trigonella foenum-Graecum (seed) - 100mg
  • Curcuma longa (rhizome) - 100mg
  • Phyllanthus embilica officinalis (fruit) - 100mg
  • Swertia chiraytia (leaf) - 80mg
  • Syzgium Cumini (seed) - 100mg
  • Neopicrorhiza Picrorhiza/Scrophulariiflora Kurroa (root) - 100mg
  • Cinnamoum verum/zeylanicum - 40 mg
  • Hydroxypropyl methylcellulose
  • Rice Flour

Primary Outcome Measures :
  1. Hemoglobin A1C [ Time Frame: 12 Weeks ]
    Hemoglobin is the oxygen-carrying component of red blood cells. In the presence of sustained elevated glucose levels, glucose non-enzymatically binds to hemoglobin, leading to the formation of glycated hemoglobin, and later, advanced glycation end products (AGEs). AGEs are responsible for many of the complications of T2DM. Thus, HbA1c, in conjunction with fasting blood glucose, is used as diagnostic criteria for T2DM (HbA1c ≥ 6.5%), and is used as a marker of glycemic control in diabetic individuals. As the life cycle of a red blood cell is approximately 90 days, serum HbA1c measurements are a snapshot of the percent of glycated hemoglobin over the prior two to three months, and thus serve as a snapshot of glycemic control in T2DM. HbA1c will be expressed as a percentage.

  2. Gamma-glutamyltransferase (GGT) [ Time Frame: 12 Weeks ]
    Concentration of the enzyme Gamma-glutamyltransferase (GGT) in the blood is considered a measure of liver inflammation and oxidative stress. Liver function markers will be expressed as IU/L.

  3. Aspartate aminotransferase (AST) [ Time Frame: 12 Weeks ]
    Concentration of the enzyme aspartate aminotransferase (AST) in the blood is considered a measure of liver inflammation. Liver function markers will be expressed as IU/L.

  4. Alanine aminotransferase (ALT) [ Time Frame: 12 Weeks ]
    Concentration of the enzyme alanine aminotransferase (ALT) in the blood is considered a measure of liver inflammation. Liver function markers will be expressed as IU/L.

  5. Homeostatic Model Assessment of Insulin Resistance [ Time Frame: 12 Weeks ]
    The Homeostatic model assessment (HOMA) of β- cell function and insulin resistance (IR) is a calculated ratio of fasting plasma insulin to glucose, and reflects the balance between hepatic glucose output and β- cell insulin secretion. It has been used in greater than 500 research publications to provide an estimate of insulin sensitivity and β- cell function, and is used to predict the level of insulin resistance. In patients with T2DM, the HOMA-IR is able to assess changes in β-cell function and IR, and thus, provide a reflection of treatment effects. The HOMA-IR will be expressed as a number, where '1' is considered normal, and anything above '1' is reflective of some degree of insulin resistance.

Secondary Outcome Measures :
  1. Fasting Blood Glucose [ Time Frame: 12 Weeks ]
    FBG, in conjunction with HbA1c, is used as a diagnostic criteria for T2DM (FBG ≥ 126 mg/dL), and is used as a marker of glycemic control in diabetic individuals. Levels are associated with future cardiac events and other complications of T2DM. FBG will be expressed in mg/dL.

  2. Estimated glomerular filtration rate [ Time Frame: 12 Weeks ]
    As estimation of the rate at which the kidneys filter and reabsorb protein based on age, ethnicity and blood creatinine.

  3. Triglycerides [ Time Frame: 12 Weeks ]
    The concentration of triglyceride-based fats in the blood is a cardiovascular risk factor.

  4. LDL:HDL ratio [ Time Frame: 12 Weeks ]
    The ratio of the concentration of low density lipoproteins (LDL) to high density lipoproteins (HDL) is a cardiovascular risk factor.

  5. BMI [ Time Frame: 12 Weeks ]
    Elevated body weight, manifesting as being overweight or obese, can cause and/or lead to exacerbations in a variety of pathologies, including T2DM, dyslipidemia, liver dysfunction, renal dysfunction, and cardiovascular disease. Thus, changes in weight are clinically meaningful in a T2DM population. This outcome measure is an important correlate and is of low burden to participants. Additionally, we will measure height in order to calculate Body Mass Index (BMI). Body weight will be expressed in pounds, height in inches, and BMI in kg/m2.

  6. Creatinine [ Time Frame: 12 weeks ]
    The concentration of creatinine in the blood is a measure of renal function.

  7. Blood urea nitrogen (BUN) [ Time Frame: 12 weeks ]
    The concentration of urea-based nitrogen in the blood is a measure of renal function.

Other Outcome Measures:
  1. PROMIS-29 Health-related Quality of Life [ Time Frame: 12 Weeks ]
    PROMIS-29 will measure health-related quality of life and is a validated, 29 question survey divided into seven sub-domains of function including physical functioning, social function, pain interference, pain intensity, sleep, depression, and anxiety.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Community-dwelling adults ≥18 and ≤ 75 years of age.
  • Have an existing diagnosis of type 2 diabetes without known complications; i.e. eye damage (retinopathy), nerve damage (diabetic peripheral neuropathy), kidney damage (diabetic kidney disease), or heart damage (recent myocardial infarction or severe congestive heart failure).
  • Must be on a stable dose (i.e. consistent dose for three months or greater) of all medications.
  • Must be on a stable dose of dietary supplements for one month prior to enrollment.
  • Have a serum hemoglobin A1c between 7% and 9.5%.
  • Able to communicate via email, fill out a computer-administered questionnaire, and to read and write in English.
  • Willing to have blood drawn at 3 separate time points.
  • Willing to take an herbal supplement three times a day, daily, for 12 weeks.
  • Willing to abstain from new anti-diabetic therapies, vitamins, minerals, dietary supplements, and lipid-lowering agents for 12 weeks.
  • Willing and able to follow the study protocol and attend study visits.
  • Approved to be eligible for study participation at the discretion of the Principal Investigators, after review of the Formal Eligibility Screen results.

Exclusion Criteria:

  • Allergy to any ingredient found in the study product (Mormordica charantia (fruit), Gymnema sylvestre (leaf), Trigonella foenum-Graecum (seed), Curcuma longa (rhizome), Phyllanthus embilica officinalis (fruit), Swertia chiraytia (leaf), Syzgium Cumini (seed), Neopicrorhiza Picrorhiza/Scrophulariiflora Kurroa (root), Cinnamoum verum/zeylanicum, Hydroxypropyl methylcellulose, Rice Flour).
  • Current use of insulin.
  • Current use of CuraLin or any dietary supplement that has the same ingredients as CuraLin (see list of ingredients above).
  • Current use of the following lipid-lowering medications: Ezetimibe (Zetia), Cholestyramine (Prevalite, Questran, Questran Light), Colesevelam (Welchol), or Colestipol (Colestid, Colestid Flavored).
  • History of myocardial infarction or stroke within the last 6 months, current coronary artery disease, unstable angina, uncontrolled hypertension (i.e. systolic > 180 or diastolic > 110), congestive heart failure, or stated history of coronary bypass surgery or heart stent placement.
  • Current active diabetic ulcers or history of diabetic neuropathy.
  • Active malignancy, with the exception of basal cell carcinoma, squamous cell carcinoma, and/or carcinoma in situ of the cervix.
  • Current diagnosis of Small Intestinal Bacterial Overgrowth (SIBO), Small Intestinal Fungal Overgrowth (SIFO), Inflammatory Bowel Disease (IBD; i.e. Crohn's or Ulcerative Colitis), or other diagnosed pathology of the gastrointestinal tract (excluding Irritable Bowel Syndrome, [IBS]).
  • Presence of an unstable and/or significant medical disorder that would compromise the participant's safety to take part in the study.
  • Planned elective surgery within the next 12 weeks.
  • Pregnant, nursing, or planning a pregnancy within the next 12 weeks.
  • Women of childbearing age not using standard birth control measures.
  • History of liver and/or kidney disease.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT05267925

Layout table for location information
United States, Oregon
National University of Natural Medicine
Portland, Oregon, United States, 97201
United States, Washington
Institute of Complementary Medicine
Seattle, Washington, United States, 98122
Sponsors and Collaborators
National University of Natural Medicine
Layout table for additonal information
Responsible Party: National University of Natural Medicine Identifier: NCT05267925    
Other Study ID Numbers: RBKK8321
First Posted: March 7, 2022    Key Record Dates
Last Update Posted: April 22, 2022
Last Verified: April 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases